NVO -15% - Shares plunged after its experimental obesity drug CagriSema failed to meet a key endpoint in a head-to-head study versus LLY tirzepatide, adding to competitive pressure in the weight-loss market. The setback comes as Novo faces rising competition despite the success of Wegovy and Ozempic. We are living through times without precedent in history. It broke the support line coming from 1987. At the same time, it also broke the monthly EMA200. The last time RSI was at this level was in 1987...
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
$NVO
NVO -15% - Shares plunged after its experimental obesity drug CagriSema failed to meet a key endpoint in a head-to-head study versus LLY tirzepatide, adding to competitive pressure in the weight-loss market. The setback comes as Novo faces rising competition despite the success of Wegovy and Ozempic.
We are living through times without precedent in history. It broke the support line coming from 1987. At the same time, it also broke the monthly EMA200. The last time RSI was at this level was in 1987...